ArticleCureus2026
Wernicke Encephalopathy as a Rare Complication of Antituberculosis Treatment: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wernicke encephalopathy (WE) is an acute neurological emergency caused by severe thiamine deficiency. Although classically associated with chronic alcoholism, it may also occur in nonalcoholic settings, including during prolonged antituberculosis treatment. We report the case of a 29-year-old woman treated for bacteriologically confirmed pulmonary tuberculosis who developed recurrent episodes of severe drug-induced hepatotoxicity, requiring treatment interruption and modification. Despite the introduction of an alternative antituberculosis regimen, she experienced persistent vomiting followed by the acute onset of cerebellar ataxia and ophthalmoplegia. Brain MRI revealed bilateral and symmetric fluid-attenuated inversion recovery hyperintensities of the medial thalami, the periaqueductal gray matter, and the mammillary bodies, consistent with WE. Plasma thiamine level was markedly reduced (55 nmol/L). High-dose IV thiamine (500 mg three times daily for five days), followed by oral supplementation, led to rapid and complete neurological recovery. WE is a rare but potentially severe complication in patients receiving antituberculosis therapy, particularly in the presence of persistent vomiting and hepatic toxicity. Early recognition and prompt treatment with thiamine are essential to prevent irreversible neurological sequelae. Preventive thiamine supplementation should be considered in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.